ACAD Quote, Financials, Valuation and Earnings

Cabaletta Bio has a net margin of 7.77% compared to ACADIA Pharmaceuticals's net margin of --. ACADIA Pharmaceuticals's return on equity of 37.45% beat Cabaletta Bio's return on equity of --.

ACADIA Pharmaceuticals has a consensus price target of $28.74, signalling upside risk potential of 27.44%. On the other hand Cabaletta Bio has an analysts' consensus of $15.67 which suggests that it could grow by 827.02%. Given that Cabaletta Bio has higher upside potential than ACADIA Pharmaceuticals, analysts believe Cabaletta Bio is more attractive than ACADIA Pharmaceuticals.

ACADIA Pharmaceuticals has a beta of 0.641, which suggesting that the stock is 35.902% less volatile than S&P 500. In comparison Cabaletta Bio has a beta of 2.705, suggesting its more volatile than the S&P 500 by 170.496%.

ACADIA Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Cabaletta Bio offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. ACADIA Pharmaceuticals pays -- of its earnings as a dividend. Cabaletta Bio pays out -- of its earnings as a dividend.

ACADIA Pharmaceuticals quarterly revenues are $244.3M, which are larger than Cabaletta Bio quarterly revenues of --. ACADIA Pharmaceuticals's net income of $19M is higher than Cabaletta Bio's net income of -$35.9M. Notably, ACADIA Pharmaceuticals's price-to-earnings ratio is 16.46x while Cabaletta Bio's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for ACADIA Pharmaceuticals is 3.77x versus -- for Cabaletta Bio. Usually stocks with elevated PS ratios are considered overvalued.

MannKind has a net margin of 7.77% compared to ACADIA Pharmaceuticals's net margin of 16.79%. ACADIA Pharmaceuticals's return on equity of 37.45% beat MannKind's return on equity of --.

ACADIA Pharmaceuticals has a consensus price target of $28.74, signalling upside risk potential of 27.44%. On the other hand MannKind has an analysts' consensus of $9.38 which suggests that it could grow by 136.74%. Given that MannKind has higher upside potential than ACADIA Pharmaceuticals, analysts believe MannKind is more attractive than ACADIA Pharmaceuticals.

ACADIA Pharmaceuticals has a beta of 0.641, which suggesting that the stock is 35.902% less volatile than S&P 500. In comparison MannKind has a beta of 0.965, suggesting its less volatile than the S&P 500 by 3.546%.

ACADIA Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. MannKind offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. ACADIA Pharmaceuticals pays -- of its earnings as a dividend. MannKind pays out -- of its earnings as a dividend.

ACADIA Pharmaceuticals quarterly revenues are $244.3M, which are larger than MannKind quarterly revenues of $78.4M. ACADIA Pharmaceuticals's net income of $19M is higher than MannKind's net income of $13.2M. Notably, ACADIA Pharmaceuticals's price-to-earnings ratio is 16.46x while MannKind's PE ratio is 39.60x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for ACADIA Pharmaceuticals is 3.77x versus 3.89x for MannKind. Usually stocks with elevated PS ratios are considered overvalued.

NovaBay Pharmaceuticals has a net margin of 7.77% compared to ACADIA Pharmaceuticals's net margin of -49.65%. ACADIA Pharmaceuticals's return on equity of 37.45% beat NovaBay Pharmaceuticals's return on equity of -461.38%.

ACADIA Pharmaceuticals has a consensus price target of $28.74, signalling upside risk potential of 27.44%. On the other hand NovaBay Pharmaceuticals has an analysts' consensus of $0.85 which suggests that it could grow by 31.62%. Given that NovaBay Pharmaceuticals has higher upside potential than ACADIA Pharmaceuticals, analysts believe NovaBay Pharmaceuticals is more attractive than ACADIA Pharmaceuticals.

ACADIA Pharmaceuticals has a beta of 0.641, which suggesting that the stock is 35.902% less volatile than S&P 500. In comparison NovaBay Pharmaceuticals has a beta of 0.443, suggesting its less volatile than the S&P 500 by 55.681%.

ACADIA Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NovaBay Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. ACADIA Pharmaceuticals pays -- of its earnings as a dividend. NovaBay Pharmaceuticals pays out -- of its earnings as a dividend.

ACADIA Pharmaceuticals quarterly revenues are $244.3M, which are larger than NovaBay Pharmaceuticals quarterly revenues of $2.4M. ACADIA Pharmaceuticals's net income of $19M is higher than NovaBay Pharmaceuticals's net income of $7.7M. Notably, ACADIA Pharmaceuticals's price-to-earnings ratio is 16.46x while NovaBay Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for ACADIA Pharmaceuticals is 3.77x versus 0.16x for NovaBay Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

Sage Therapeutics has a net margin of 7.77% compared to ACADIA Pharmaceuticals's net margin of -442.4%. ACADIA Pharmaceuticals's return on equity of 37.45% beat Sage Therapeutics's return on equity of -64.19%.

ACADIA Pharmaceuticals has a consensus price target of $28.74, signalling upside risk potential of 27.44%. On the other hand Sage Therapeutics has an analysts' consensus of $8.73 which suggests that it could fall by -4.4%. Given that ACADIA Pharmaceuticals has higher upside potential than Sage Therapeutics, analysts believe ACADIA Pharmaceuticals is more attractive than Sage Therapeutics.

ACADIA Pharmaceuticals has a beta of 0.641, which suggesting that the stock is 35.902% less volatile than S&P 500. In comparison Sage Therapeutics has a beta of 0.294, suggesting its less volatile than the S&P 500 by 70.557%.

ACADIA Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Sage Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. ACADIA Pharmaceuticals pays -- of its earnings as a dividend. Sage Therapeutics pays out -- of its earnings as a dividend.

ACADIA Pharmaceuticals quarterly revenues are $244.3M, which are larger than Sage Therapeutics quarterly revenues of $14.1M. ACADIA Pharmaceuticals's net income of $19M is higher than Sage Therapeutics's net income of -$62.2M. Notably, ACADIA Pharmaceuticals's price-to-earnings ratio is 16.46x while Sage Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for ACADIA Pharmaceuticals is 3.77x versus 11.79x for Sage Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.